Drug Combo Proves Powerful Against Lung Cancer Monsey NY

A two-drug combination treatment in Monsey proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
DORIS PONCE, MD
(914) 346-5696
93 Shoreview Drive
Yonkers, NY
JESSICA HOCHBERG, MD
(914) 493-7997
95 Grasslands Road
Valhalla, NY
Norman Lester Rosen, MD
914-965-2060
984 N Broadway
Yonkers, NY
Julia Glade Bender, MD
212-305-5808
703 Main St
Paterson, NJ
Sushil Bhardwaj
(845) 368-8500
255 Lafayette Ave
Suffern, NY
VALIERE ALCENA, MD
(914) 682-8020
37 Davis Avenue
White Plains, NY
MICHELLE BOYAR, MD
(646) 227-3813
777 N Broadway
Tarrytown, NY
Asim Aijaz, MD
914-493-8374
12 Reeback Dr
Valhalla, NY
Khalid Omar Dar, MD
212-280-3514
9 Park Avenue Ter
Bronxville, NY
Data Provided by:
      

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Monsey NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Exercise for Prostate Cancer Monsey NY
- Fungal Infection Treatments Monsey NY
- Exercise for Breast Cancer Survival Monsey NY
- Delayed Prostate Cancer Therapy Monsey NY
- Genetic Clues for Skin Cancer Therapies Monsey NY
- Risks for Childhood Cancer Survivors Monsey NY
- Hormone Therapy for Breast Cancer Monsey NY
- Hormone Therapy for Lung Cancer Monsey NY